AstraZeneca (LSE:AZN) told investors that its SERENA-4 Phase III trial of Etcamah (camizestrant) combined with palbociclib did not meet its primary endpoint of statistically significant progression-free survival improvement.
The trial tested the combination against an aromatase inhibitor plus palbociclib in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer who had not yet received treatment for advanced disease.
A numerical improvement in progression-free survival was observed despite the miss, and the drugmaker reported no new safety concerns across the 1,371-patient global study.
Susan Galbraith, AstraZeneca's Executive Vice President of Oncology Haematology R&D, said the result "sharpens our focus on maximising the number of patients who can benefit from Etcamah today" based on the drug's existing approval.
That approval, granted in the US, EU, Japan and other markets, covers Etcamah in combination with CDK4/6 inhibitors for patients who develop an ESR1 mutation during first-line endocrine therapy, based on the separate SERENA-6 trial.
Etcamah remains the only oral selective estrogen receptor degrader shown to benefit patients in that ESR1-mutation setting.
AstraZeneca is now running the CAMBRIA-1 and CAMBRIA-2 Phase III trials, covering roughly 10,000 patients, to test Etcamah in earlier-stage breast cancer.
Data from SERENA-4 will be shared in due course, the company said.
News Intelligence what this means for the company
AstraZeneca's SERENA-4 trial failed to meet its primary endpoint of statistically significant progression-free survival improvement for camizestrant (Etcamah) plus palbociclib in first-line advanced breast cancer, despite showing a numerical benefit in a 1,371-patient study. The miss narrows the drug's near-term commercial opportunity: Etcamah's current approval covers use in patients who develop an ESR1 mutation during first-line endocrine therapy, a smaller population than the first-line unselected cohort tested here. The company now relies on earlier-stage trials (CAMBRIA-1 and CAMBRIA-2, covering ~10,000 patients) to expand the drug's label.
SERENA-4's failure removes a potential near-term label expansion that could have broadened Etcamah's addressable market in first-line breast cancer. The drug's value proposition now rests on its existing ESR1-mutation indication and the outcome of the CAMBRIA trials in earlier-stage disease; no new safety signals emerged, but the numerical PFS benefit without statistical significance leaves the clinical case for first-line combination therapy unproven.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
